The 2022 Pediatric Early Development Symposium (PEDS): Leveraging Big Data to Advance Pediatric Clinical Trials was another collaborative success!
This event convened leaders from all areas of pediatric oncology – pharmaceutical and biotechnology companies, clinical research organizations, academic leaders, parents and patient advocates, venture capitalists, regulators, and like-minded partners.
The recurring themes throughout the Symposium were:
- Pediatric drug development must be treated as a global enterprise
- More collaboration is necessary between investigators (academics) and organizations, including industry, to generate data that move regulatory requirements forward in relevant targets
- There must be a concerted effort to improve data collection through quality standards and simplification
Derived from the many discussions, questions from attendees, and group conversations over the three-day symposium, we are pleased to share the 2022 PEDS Impact Statement, outlining three key impact areas CureSearch will address over the next year.
